USPTO Examiner LEE JAE W - Art Unit 1656

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19328055PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDESSeptember 2025December 2025Allow300YesNo
19310812REVERSE TRANSCRIPTASE VARIANTSAugust 2025November 2025Allow300YesNo
19212289STABILIZATION OF TRYPTAMINES BY DENATURING ENZYMES, OPTIMIZING IONIZATION STATES, AND CONTROLLING CONFOUNDING VARIABLESMay 2025August 2025Allow301YesNo
18984162CRISPR/CAS SCREENING PLATFORM TO IDENTIFY GENETIC MODIFIERS OF TAU SEEDING OR AGGREGATIONDecember 2024May 2025Allow500YesNo
18870088METHOD FOR PRODUCING GUANIDINO ACETIC ACID (GAA)November 2024February 2025Allow300YesNo
18948388COMPOSITION COMPRISING COLLAGENASE, CALCIUM, HISTIDINE, AND GLYCINE, AND METHOD FOR STABILIZING COLLAGENASENovember 2024October 2025Allow1120NoNo
18824681PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDESSeptember 2024November 2024Allow200YesNo
18648209PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDESApril 2024August 2024Allow300YesNo
18625448ALDEHYDE DEHYDROGENASE PRODUCING BACTERIA AND METHODS OF USING SAMEApril 2024July 2024Allow300YesNo
18602534GENETICALLY MODIFIED PROBIOTICS FOR ORAL DELIVERY OF RENIN-ANGIOTENSIN RELATED THERAPEUTIC PROTEINS AND PEPTIDESMarch 2024February 2026Allow2300YesNo
18598286SYSTEMS FOR DETERMINING ADAMTS13 ENZYME ACTIVITYMarch 2024June 2025Allow1501YesNo
18595600ALPHA-AMYLASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAMEMarch 2024May 2025Allow1401YesNo
18586709Polypeptides having Peptidoglycan Degrading Activity and Polynucleotides Encoding SameFebruary 2024January 2025Allow1100YesNo
18432505MOLECULES FOR ORGANELLE-SPECIFIC PROTEIN DELIVERYFebruary 2024March 2025Allow1300YesNo
18431554ACTIVE LOW MOLECULAR WEIGHT VARIANTS OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2)February 2024September 2025Abandon2001NoNo
18431662RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USEFebruary 2024February 2025Allow1300YesNo
18424952MODIFIED IMMUNE CELLS HAVING ENHANCED FUNCTION AND METHODS FOR SCREENING THE SAMEJanuary 2024January 2025Allow1100YesNo
18416843ICAM-1 TARGETED FUSION ENZYMESJanuary 2024February 2025Allow1300YesNo
18410876PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDESJanuary 2024March 2024Allow200YesNo
18410949PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDESJanuary 2024April 2024Allow300YesNo
18409535TREATMENT OF ABNORMAL BONE CONDITIONS IN ACID SPHINGOMYELINASE DEFICIENCY PATIENTSJanuary 2024January 2026Abandon2420YesNo
18405674VARIANT MALTOHEXAOSE-FORMING ALPHA-AMYLASE VARIANTSJanuary 2024February 2025Allow1300YesNo
18390884MOLECULES FOR ORGANELLE-SPECIFIC PROTEIN DELIVERYDecember 2023May 2024Allow500YesNo
18525460HUMANIZED CELL LINENovember 2023October 2024Allow1100YesNo
18502499CRISPR/CAS SCREENING PLATFORM TO IDENTIFY GENETIC MODIFIERS OF TAU SEEDING OR AGGREGATIONNovember 2023September 2024Allow1000NoNo
18386621Mutant Taq Polymerase Providing Faster AmplificationNovember 2023February 2025Allow1500YesNo
18379079Biological Production of Multi-Carbon Compounds from MethaneOctober 2023December 2025Allow2610YesNo
18483460PROGRAMMED DNA-DRIVEN SELF-ASSEMBLED RNA HYDROGELOctober 2023September 2025Abandon2401NoNo
18483386PROGRAMMED DNA-DRIVEN SELF-ASSEMBLED RNA HYDROGELOctober 2023November 2025Allow2500YesNo
18472540KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONESeptember 2023August 2024Allow1110YesNo
18454701COMPOSITIONS AND METHODS FOR TREATMENT OF HOMOCYSTINURIAAugust 2023September 2024Allow1200YesNo
18450994NUCLEIC ACID ENCODING MODIFIED MEMBRANE TYPE SERINE PROTEASE 1 (MTSP-1) POLYPEPTIDES AND METHODS OF USEAugust 2023August 2024Allow1200YesNo
18357617Compositions and Methods for Treating Celiac Sprue DiseaseJuly 2023January 2025Allow1800YesNo
18355990ACYL-ACP Reductase With Improved PropertiesJuly 2023August 2024Allow1300YesNo
18351198COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTIONJuly 2023December 2024Allow1700YesNo
18345783METHODS AND COMPOSITIONS FOR IMPROVING PLANT TRAITSJune 2023August 2025Allow2511YesNo
18340083FCE MRNA CAPPING ENZYME COMPOSITIONS, METHODS AND KITSJune 2023July 2024Allow1300YesNo
18333344METHODS AND COMPOSITIONS FOR IN VIVO GENE EDITING BASED CELL-TYPE-SPECIFIC CELLULAR ENGINEERINGJune 2023July 2024Allow1300YesNo
18208272COMPOSITIONS OF MATTER FOR DETECTION ASSAYSJune 2023October 2023Allow400YesNo
18265002ENGINEERED MICROORGANISMSJune 2023March 2026Allow3400YesNo
18204337COMPOSITIONS OF MATTER FOR DETECTION ASSAYSMay 2023September 2023Allow300YesNo
18316880SYSTEMS AND METHODS FOR ONE-SHOT GUIDE RNA (ogRNA) TARGETING OF ENDOGENOUS AND SOURCE DNAMay 2023November 2024Allow1900YesNo
18313955PROCESS OF EXTRACTING OIL FROM THIN STILLAGEMay 2023August 2024Allow1500YesNo
18251712MACROPINOCYTOSIS SELECTIVE MONOBODY-DRUG CONJUGATESMay 2023January 2026Allow3300YesNo
18310448PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDESMay 2023December 2023Allow701YesNo
18139481PLATFORM FOR EXPRESSING PROTEIN OF INTEREST IN LIVERApril 2023June 2024Allow1410YesNo
18304286PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDESApril 2023March 2024Allow1100YesNo
18032999COMPOSITIONS AND METHODS RELATED TO MEGAKARYOCYTE-DERIVED EXTRACELLULAR VESICLES FOR TREATING MYELOPROLIFERATIVE NEOPLASMSApril 2023February 2026Allow3300YesNo
18301790PROCESSES FOR THE PRODUCTION OF TRYPTAMINESApril 2023December 2025Allow3211YesNo
18130300GENOME EDITING METHODApril 2023July 2024Allow1600YesNo
18194471PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDESMarch 2023June 2024Allow1500YesNo
18193002BRIGHT AND STABLE RED FLUORESCENT PROTEINMarch 2023January 2026Allow3400YesNo
18187102Compositions and methods for improved malonyl-CoA biosynthesis using 2-stage dynamic metabolic controlMarch 2023April 2025Allow2521YesNo
18185726RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCESMarch 2023March 2025Allow2401YesNo
18178048METHODS AND COMPOSITIONS FOR EVOLVING BASE EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE)March 2023March 2025Allow2401YesNo
18177672SARS-CoV-2 Vaccines and AntibodiesMarch 2023December 2025Allow3300YesNo
18023891SINGLE-CHAIN CORONAVIRUS VIRAL MEMBRANE PROTEIN COMPLEXESFebruary 2023December 2025Allow3300YesNo
18170045IN VITRO GLYCOSYLATION OF PROTEINS AND ENZYMESFebruary 2023May 2024Allow1500YesNo
18021270ENGINEERED POLYMERASES AND METHODS OF USING THE SAMEFebruary 2023August 2025Allow3000YesNo
18167119STEVIOL GLYCOSIDE TRANSPORTFebruary 2023May 2024Allow1500YesNo
17764925MNEP MONOMER VARIANT AND APPLICATION THEREOFFebruary 2023August 2025Allow4100YesNo
18106420COMPOSITIONS OF MATTER FOR DETECTION ASSAYSFebruary 2023May 2023Allow300YesNo
18160947ENGINEERED POLYMERASES WITH REDUCED SEQUENCE-SPECIFIC ERRORSJanuary 2023June 2023Allow400YesNo
18016440IMMUNOGLOBULIN BINDING PROTEINS FOR AFFINITY PURIFICATIONJanuary 2023November 2025Allow3401YesNo
18089023SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH OPTIMIZED FUNCTIONAL CRISPR-CAS SYSTEMSDecember 2022December 2024Allow2400YesNo
18011785PRO-MICROBIAL SURFACEDecember 2022August 2025Allow3200YesNo
18058823MODIFIED CAS9 PROTEIN, AND USE THEREOFNovember 2022July 2024Allow2000YesNo
18058703THERAPEUTICS AND POINT OF CARE LATERAL-FLOW TEST FOR VIRUS AND ANTIBODIES USING TAGGED ASSEMBLED PROTEINSNovember 2022September 2023Allow1001YesNo
17927337METHODS AND COMPOSITIONS TO SPREAD PROTEIN CARGOES ACROSS MULTI-NUCLEATED CELLSNovember 2022February 2026Allow3901YesNo
17999260COMPOSITIONS AND METHODS FOR DNA CYTOSINE CARBOXYMETHYLATIONNovember 2022February 2026Allow3901YesNo
18055718SYSTEMS, METHODS, AND COMPOSITIONS FOR CORRECTION OF FRAMESHIFT MUTATIONSNovember 2022July 2024Allow2000YesNo
17998543EMID2 PROTEIN AS ANTI-CANCER TREATMENTNovember 2022February 2026Abandon3910YesNo
17924177STRUCTURALLY MODIFIED CHIMERIC POLYPEPTIDE OF HUMAN PAPILLOMAVIRUS, RECOMBINANT PROTEIN COMPRISING SAME POLYPEPTIDE, AND USE OF SAME PROTEINNovember 2022July 2025Allow3200YesNo
18052519METHODS AND COMPOSITIONS FOR MAKING BACTERIOCINS AND ANTIMICROBIAL PEPTIDESNovember 2022May 2024Allow1800YesNo
18048548Compositions, Methods, and Applications of a Synthetic SurfactantOctober 2022August 2025Allow3400YesNo
17920410HIGHLY ALKALINE TEXTILE DETERGENT COMPRISING PROTEASEOctober 2022July 2025Allow3300YesNo
17920407HIGHLY ALKALINE TEXTILE WASHING AGENT COMPRISING PROTEASEOctober 2022July 2025Allow3300YesNo
18047589MODIFIED HELICASESOctober 2022November 2024Allow2501YesNo
18047019MODIFIED HELICASESOctober 2022November 2024Allow2501YesNo
17765921TISSUE ADHESION COMPOSITION WITH BIO-TISSUE ADHESIVENESS AND BONDING FORCE AND PREPARATION METHOD THEREFOROctober 2022January 2026Abandon4601NoNo
17918835SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOFOctober 2022November 2025Allow3701YesNo
17995794GALECTIN-1 IMMUNOMODULATION AND MYOGENIC IMPROVEMENTS IN MUSCLE DISEASES AND AUTOIMMUINE DISORDERSOctober 2022January 2026Abandon3910NoNo
17960210GENE KNOCKOUT OF VARIANT NRF2 FOR TREATMENT OF CANCEROctober 2022March 2024Allow1700NoNo
17960224GENE KNOCKOUT OF VARIANT NRF2 FOR TREATMENT OF CANCEROctober 2022March 2024Allow1700NoNo
17959089MATERIALS AND METHODS FOR TREATMENT OF PAIN RELATED DISORDERSOctober 2022June 2025Allow3211YesNo
17931352Enzyme Based System for Production of Messenger RNA with Increased Transfection EfficiencySeptember 2022July 2025Allow3400YesNo
17943127Flp-TAL RECOMBINASESSeptember 2022February 2024Allow1700YesNo
17940797REVERSE TRANSCRIPTASE VARIANTSSeptember 2022December 2022Allow300YesNo
17930626COMPOSITIONS OF ANTI-VIRAL PEPTIDES AND METHODS OF USE THEREOFSeptember 2022June 2025Allow3400YesNo
17802018CHIMERIC RECEPTORS FOR USE IN ENGINEERED CELLSAugust 2022February 2026Abandon4201NoNo
17893530ORGANELLE-TARGETED GENETICALLY-ENCODED VOLTAGE INDICATORS AND METHODS OF USE THEREOFAugust 2022July 2023Allow1100YesNo
17798524EXOSOME COMPRISING PHOTOCLEAVABLE PROTEIN, AND USE THEREOFAugust 2022May 2025Allow3300YesNo
17878657Recombinant expression platform, constructs and methods for expression of Difficult to Express Proteins (DTE-Ps)August 2022October 2025Allow3901YesNo
17815453RNA-GUIDED NUCLEASES AND DNA BINDING PROTEINSJuly 2022April 2024Allow2100YesNo
17814972LONG CHAIN DIBASIC ACID WITH LOW CONTENT OF LONG CHAIN DIBASIC ACID IMPURITY OF SHORTER CARBON-CHAIN AND PREPARATION METHOD THEREOFJuly 2022February 2024Allow1900YesNo
17870336DNase H Activity of Neisseria Meningitidis Cas9July 2022May 2024Allow2200NoNo
17758959ANTI-DINITROPHENOL CHIMERIC ANTIGEN RECEPTORSJuly 2022November 2025Allow4001YesNo
17812712CHIMERIC POLYPEPTIDESJuly 2022June 2025Allow3500YesNo
17812400RECOGNITION SEQUENCES FOR I-CREI-DERIVED MEGANUCLEASES AND USES THEREOFJuly 2022June 2024Abandon2310NoNo
17812182LACTOBACILLUS PARACASEI TCI727 AND METHOD FOR PROMOTING CALCIUM ABSORPTION BY USING LACTOBACILLUS PARACASEI TCI727/OR ITS METABOLITESJuly 2022January 2024Allow1810NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LEE, JAE W.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
4
Examiner Affirmed
3
(75.0%)
Examiner Reversed
1
(25.0%)
Reversal Percentile
37.8%
Lower than average

What This Means

With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
49
Allowed After Appeal Filing
7
(14.3%)
Not Allowed After Appeal Filing
42
(85.7%)
Filing Benefit Percentile
16.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 14.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner LEE, JAE W - Prosecution Strategy Guide

Executive Summary

Examiner LEE, JAE W works in Art Unit 1656 and has examined 962 patent applications in our dataset. With an allowance rate of 74.9%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 28 months.

Allowance Patterns

Examiner LEE, JAE W's allowance rate of 74.9% places them in the 40% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by LEE, JAE W receive 0.96 office actions before reaching final disposition. This places the examiner in the 8% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by LEE, JAE W is 28 months. This places the examiner in the 67% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +60.6% benefit to allowance rate for applications examined by LEE, JAE W. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 29.9% of applications are subsequently allowed. This success rate is in the 58% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 27.0% of cases where such amendments are filed. This entry rate is in the 38% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 42% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 86.7% of appeals filed. This is in the 80% percentile among all examiners. Of these withdrawals, 84.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 51.6% are granted (fully or in part). This grant rate is in the 51% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 10.3% of allowed cases (in the 94% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.3% of allowed cases (in the 53% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.